Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells

Brazilian Journal of Medical and Biological Research

Volumn 34, Issue 6, 2001, Pages 699-709

  Nader, H B ^a   Pinhal, M A S ^a   Bau E C ^a   Castro, R A B ^a   Medeiros, G F ^b   Chavante, S F ^b   Leite, E L ^b   Trindade, E S ^a   Shinjo, S K ^a   Rocha, H A O ^b   Tersariol, I L S ^c   Mendes, A ^a   Dietrich, C P ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO NORTE   (Brazil)

^c UNIVERSIDADE DE MOGI DAS CRUZES   (Brazil)

Author keywords

Antithrombotic agents; Antithrombotic agents, development for clinical use; Crustacean heparin like compounds, antithrombotic activity; Heparan sulfate, antithrombotic activity; Heparin, anticlotting activity; Low molecular weight heparins, preparation and antithrombotic activity; Vascular endothelial cells

Indexed keywords

ANTICOAGULANT AGENT; APROSULATE; ARDEPARIN; CHONDROITIN SULFATE; CY 222; DALTEPARIN; DERMATAN SULFATE; DEXTRAN SULFATE; ENOXAPARIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN COFACTOR II; HEPARIN DERIVATIVE; HEPARINOID; LACTOBIONIC ACID; LOW MOLECULAR WEIGHT HEPARIN; LW 10282; NADROPARIN; OP 386; PARNAPARIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SULEPAROIDE; TINZAPARIN;

ANTICOAGULATION; ARTEMIA; ARTERY THROMBOSIS; BLOOD CLOTTING; CATTLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; PANCREAS; REVIEW; SHRIMP; SYNTHESIS; THROMBOCYTOPENIA; TUNA; VEIN THROMBOSIS;

ARTEMIA; ARTEMIA FRANCISCANA; BOS TAURUS; BOVINAE; CRUSTACEA; DECAPODA (CRUSTACEA); PONTOPORIA BLAINVILLEI; SCOMBRIDAE GEN. SP.;

EID: 0034952660     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2001000600002     Document Type: Review

References (30)

1. Fareed JW, Hoppensteadt D & Bick RL (2000). An update of heparins at the beginning of the new millenium. Seminars in Thrombosis and Hemostasis, 26: 5-21.
2. Silva ME & Dietrich CP (1975). Structure of heparin. Characterization of the products formed from heparin by the action of a heparinase and a heparitinase from Flavobacterium heparinum. Journal of Biological Chemistry, 250: 6841-6846.
3. Dietrich CP, Nader HB & McDuffie NM (1975). Electrofocusing of heparin. Presence of 21 monomeric and dimeric molecular species in heparin preparations. Anais da Academia Brasileira de Ciências, 47: 301-309.
4. Nader HB, McDuffie NM & Dietrich CP (1974). Heparin fractionation by electrofocusing: Presence of 21 components of different molecular weights Biochemical and Biophysical Research Communications, 57: 488-493.
5. McDuffie NM, Nader HB & Dietrich CP (1975). Electrofocusing of heparin. Fractionation of heparin into 21 components distinguishable from other acidic mucopolysaccharides. Biopolymers, 14: 1473-1486.
6. Bianchini P, Osima B, Parma B, Dietrich CP, Takahashi HK & Nader HB (1985). Structural studies and in vivo and in vitro pharmacological activities of heparin fractions and fragments prepared by chemical and enzymatic depolymenzation. Thrombosis Research, 40: 49-58.
7. Fareed J, Jeske W, Hoppensteadt D, Clarizio R & Walenga JM (1998). Low-molecular-weight heparins: pharmacologic profile and product differentiation. American Journal of Cardiology, 82: 3L-10L.
8. Fareed J, Hoppensteadt D, Jeske W, Clarizio R & Walenga JM (1998). Low molecular weight heparins: are they different? Canadian Journal of Cardiology, 14: 28E-34E.
9. Bagge L, Wahlberg T, Holmer E, Tydén H, Nyström SO & Malm T (1994). Low-molecular-weight heparin (Fragmin) versus heparin for anticoagulation during cardiopulmonary bypass in open heart surgery, using a pig model. Blood Coagulation and Fibrinolysts, 5: 265-272.
10. Colwell Jr CW (1994). Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis Orthopedics, 17: 5-7.
11. Haas S & Flosbach CW (1993). Prevention of postoperative thromboembolism with Enoxaparin in general surgery: a German multicenter trial. Seminars in Thrombosis and Hemostasis, 19: 164-173.
12. Hirsh J (1996). Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis. Haemostasia, 26: 189-198.
13. Martineau P & Tawil N (1998). Low-molecular-weight heparins in tne treatment of deep-vein thrombosis. Annals of Pharmacotherapy, 32: 588-598.
14. Dietrich CP, Shinjo SK, Moraes FA, Castro RAB, Mendes A, Gouvea TC & Nader HB (1999). Structural features and bleeding activity of commercial LMW-heparins: Neutralization by ATP and protamine. Seminars in Thrombosis and Hemostasis, 25: 43-50.
15. Dietrich CP, Paiva JF, Castro RAB, Chavante SF, Jeske W, Fareed J, Gorin PAJ, Mendes A & Nader HB (1999). Structural features and anticlotting activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochimica et Biophysics Acta, 1428: 273-283.
16. Bianchini P, Osima B, Parma B, Nader HB & Dietrich CP (1985). Lack of correlation between in vitro and in vivo antithrombotic activity of heparin fractions and related compounds: Heparan sulfate as an antithrombotic agent in vivo. Thrombosis Research, 40: 597-607.
17. Mattar L, Maffei FHA, Nader HB & Dietrich CP (1994). Effect of different glycosaminoglycans in a guinea-pig carotid artery thrombosis model. Thrombosis Research, 75: 591-599.
18. Chavante SF, Santos EA, Oliveira FW, Guerrini M, Torri G, Casu B, Dietrich CP & Nader HB (2000). A novel heparan sulfate with high degree of N-sulfation and high heparin cofactor-II activity from the brine shrimp Artemia franciscana. International Journal of Biological Macromolecules, 27: 49-57.
19. Jeske W, Nelson S, Lee T, Chen J & Fareed J (1993). Tissue factor pathway inhibitor (TFPI) release induced by a novel sulfonic acid polyphenol (GL522) following IV administration to cynomolgus monkeys. FASEB Journal, 7: 210 (Abstract).
20. Jeske W, Lojewski B & Fareed J (1992). Biochemical and pharmacologic studies on a novel polysulfonated oral antithrombotic agent (GL-522-Y-1). Blood, 80: 322a (Abstract).
21. Leite EML, Medeiros MGL, Rocha AAO, Farias GGM, Silva LF, Chavante SF, Dietrich CP & Nader HB (1998). Structure and pharmacological activities of a sulfated glucuronoxylofucan from the algae Spatoglossum xhröeden. Plant Science, 132: 215-228.
22. Colburn P & Buonassisi V (1982). Anticlotting activity of endothelial cell cultures and heparan sulfate proteoglycans. Biochemical and Biophysical Research Communications, 104: 220-227
23. Buonassisi V & Venter JC (1976). Hormone and neurotransmitter receptors in an established vascular endothelial cell line. Proceedings of the National Academy of Sciences, USA, 73: 1612-1616.
24. Takahashi K & Sawasaki Y (1991). Human endothelial cell line, ECV304, produces pro-urokinase in vitro. In vitro Cellular and Developmental Biology, 27: 766-768.
25. Nader HB, Buonassisi V, Colburn P & Dietrich CP (1989). Heparin stimulates the synthesis and modifies the sulfation pattern of heparan sulfate proteoglycan from endothelial cells. Journal of Cellular Physiology, 140: 305-310.
26. Pinhal MAS, Santos IAN, Silva IF, Dietrich CP & Nader HB (1995). Stimulation of the synthesis of an antithrombotic heparan sulfate from endothelial cells by heparin and its fragments. Thrombosis and Haemostasis, 74: 1169-1174.
27. Pinhal MAS, Walenga JM, Jeske W, Hoppensteadt D, Dietrich CP, Fareed J & Nader HB (1994). Antithrombotic agents stimulate the synthesis and modify the sulfation pattern of a heparan sulfate proteoglycan from endothelial cells. Thrombosis Research, 74: 143-153.
28. Nader HB, Porcionatto MA, Moraes CT & Dietrich CP (1990). Purification and substrate specificity of heparinase, heparitinase I and heparitinase II from Flavobacterium heparinum. Journal of Biological Chemistry, 265: 6807-6813.
29. Blanchin P, Osima B, Parma B, Nader HB & Dietrich CP (1982). Pharmacological activities of heparins obtained from different tissues: Enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography. Journal of Pharmacology and Experimental Therapeutics, 220: 406-410.
30. Lasker SE & Stivala SS (1966). Physico-chemical studies of fractionated bovine heparin. I. Some dilute solution properties. Archives of Biochemistry and Biophysics, 115: 360-372.